Literature DB >> 11903741

Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics.

J T Edwards1, G L Radford-Smith, T H Florin.   

Abstract

BACKGROUND: Narcotic addiction can be a significant problem in inflammatory bowel disease (IBD). However, there are few published reports about this problem.
METHODS: All patients prescribed narcotics chronically in the absence of demonstrable organic pathology were identified on the computerized Brisbane IBD Research Group database (n=332 patients with informative data as of 1 January 1999). Individual case records were reviewed with regard to clinical, psychiatric and social characteristics of these patients, and the prevalence of psychiatric disorders were compared with a control group of IBD patients.
RESULTS: Eleven patients were identified. Nine had complete datasets, eight with Crohn's disease (CD), of which six had previous stricturing ileal disease, and one patient had ulcerative colitis, making a prevalence of 2.7% of IBD patients and 5.1% of CD patients. A 67% prevalence of a psychiatric disorder in narcotic users was significantly greater than the 8% prevalence in the control group of IBD patients (odds ratio 22, 95% CI 3.24-177).
CONCLUSIONS: A significant proportion of IBD patients without demonstrable organic pathology were chronic narcotic users. Psychiatric disorders are common in this subgroup, as with chronic functional abdominal pain syndromes. It is suggested that inappropriate narcotic use in IBD patients can be reduced by appreciating that narcotics are a temporary therapy only for IBD patients, and awareness of pre-existing social and psychiatric disorders, which not only impact on clinical presentation of pain, but also help define the subgroup of patients who are at risk of narcotic misuse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11903741     DOI: 10.1046/j.1440-1746.2001.02468.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  28 in total

1.  "Cobblestone" appearance of the ascending colon.

Authors:  Takahito Hayashi; Carla Schönfeld; Michael Tsokos
Journal:  Forensic Sci Med Pathol       Date:  2012-06-05       Impact factor: 2.007

2.  The putative role of endogenous and exogenous opiates in inflammatory bowel disease.

Authors:  S Collins; M Verma-Gandhu
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 3.  Pain and inflammatory bowel disease.

Authors:  Klaus Bielefeldt; Brian Davis; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

Review 4.  Strategies to Identify and Reduce Opioid Misuse Among Patients with Gastrointestinal Disorders: A Systematic Scoping Review.

Authors:  Salva N Balbale; Itishree Trivedi; Linda C O'Dwyer; Megan C McHugh; Charlesnika T Evans; Neil Jordan; Laurie A Keefer
Journal:  Dig Dis Sci       Date:  2017-08-05       Impact factor: 3.199

5.  Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Authors:  Mohamed Noureldin; Peter D R Higgins; Shail M Govani; Shirley Cohen-Mekelburg; Brooke C Kenney; Ryan W Stidham; Jennifer F Waljee; Akbar K Waljee
Journal:  Aliment Pharmacol Ther       Date:  2018-11-14       Impact factor: 8.171

6.  Narcotic use for inflammatory bowel disease and risk factors during hospitalization.

Authors:  Millie D Long; Edward L Barnes; Hans H Herfarth; Douglas A Drossman
Journal:  Inflamm Bowel Dis       Date:  2011-07-07       Impact factor: 5.325

7.  Electroacupuncture inhibits visceral pain via adenosine receptors in mice with inflammatory bowel disease.

Authors:  Tengfei Hou; Hongchun Xiang; Lingling Yu; Wen Su; Yang Shu; Hongping Li; He Zhu; Lixue Lin; Xuefei Hu; Shangdong Liang; Hong Zhang; Man Li
Journal:  Purinergic Signal       Date:  2019-06-11       Impact factor: 3.765

8.  Predictors of Chronic Opioid Use in Newly Diagnosed Crohn's Disease.

Authors:  Nathan J Pauly; Lamprinos Michailidis; Michael G Kindred; Deborah Flomenhoft; Michelle R Lofwall; Sharon L Walsh; Jeffery C Talbert; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

9.  Neonatal immune challenge followed by adult immune challenge induces epigenetic-susceptibility to aggravated visceral hypersensitivity.

Authors:  J E Aguirre; J H Winston; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2017-04-25       Impact factor: 3.598

10.  Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study.

Authors:  T Card; J West; R Hubbard; R F A Logan
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.